Table 1 Baseline data and outcome variables in 15 patients treated with ezetimibe for 8 weeks
Variables | Baseline | Treatment | % change | P* |
|---|---|---|---|---|
Dietary assessment | ||||
Total calories (kj/d) | 8037 [6728–9033] | 7657 [6841–11167] | -4.7% | .55 |
Total fat (g/d) | 93 [76–105] | 86 [83–115] | -7.5% | .53 |
Saturated fatty acids (g/d) | 26 [17–31] | 24 [19–32] | -7.7% | .94 |
Cholesterol (mg/d) | 254 [223–340] | 294 [247–346] | 15.7 | .81 |
Phytosterols (mg/d) | 184 [141–211] | 156 [129–193] | -15.2% | .09 |
Body weight (kg) | 73.0 [61.2-80.1] | 73.1 [63.9-80.8] | 0.1% | 1 |
Waist circumference (cm) | 92.5 [85.7-96] | 95.0 [88–100] | 2.7% | .55 |
Lipids and apos | ||||
Total cholesterol (mmol/L) | 5.87 [5.46-6.54] | 5.2 [4.89-5.61] | -11.4% | .002 |
LDL-cholesterol (mmol/L) | 3.93 [3.46-4.27] | 3.13 [2.95-3.44] | -20.4% | .003 |
nonHDL-cholesterol (mmol/L) | 4.63 [4.29-5.30] | 4.01 [3.59-4.42] | -13.4% | .002 |
HDL-cholesterol (mmol/L) | 1.21 [1.11-1.47] | 1.19 [1.03-1.34] | -2.1% | .11 |
Triglycerides (mmol/L) | 1.64 [1.15-2.04] | 1.42 [1.15-2.29] | -13.1% | .46 |
Apo A1 (g/L) | 1.47 [1.39-1.53] | 1.54 [1.44-1.59] | 4.7% | 1 |
Apo B (g/L) | 1.21 [1.09-1.42] | 1.10 [0.95-1.24] | -9.1% | .02 |
C-reactive protein (mg/L) | 1.2 [0.4-1.6] | 0.6 [0.5-3.5] | -50% | .61 |
Plasma viral load (copies/mL) | 49 [49–49] | 49 [49–49] | 0% | .65 |
CD4 cell count (cells/μL) | 503 [353–802] | 499 [323–794] | -0.8% | .65 |
Lathosterol (μmol/L) | 7.08 [5.19-9.43] | 9.97 [6.68-12.67] | 40.9% | .015 |
Lathosterol/cholesterol | 1.26 [0.84-1.54] | 1.93 [1.37-2.40] | 53.2% | .005 |
Campesterol (μmol/L) | 27.78 [20.22-38.95] | 14.78 [10.72-18.51] | -46.8% | .001 |
Campesterol/cholesterol | 4.65 [3.23-6.36] | 2.62 [1.98-3.53] | -43.6% | .001 |
Sitosterol (μmol/L) | 22.96 [20.34-33.25] | 14.77 [10.96-19.52] | -35.7% | .001 |
Sitosterol/cholesterol | 4.46 [3.70-6.09] | 2.59 [2.17-3.76] | -41.9% | .001 |